Skip to main content
SpringerLink
Log in

Metipranolol

Pharmacology of Beta-blocking Agents and Use of Metipranolol in Ophthalmology

  • Conference proceedings
  • © 1984

Overview

Editors:
  1. Hanns-Jürgen Merté

    1. Isar — Technical University, Munich, Federal Republic of Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (17 papers)

  1. Front Matter

    Pages I-XI
    Download chapter PDF

  2. New Directions in Glaucoma Therapy — Introductory Speech at the Metipranolol Symposium

    • H.-J. Merté
    Pages 1-2

  3. Receptor-mediated Effects of Drugs on the Eye

    • D. Palm
    Pages 3-21

  4. Present Day Possibilities of Glaucoma Therapy

    • H.-J. Merté, J. Stryz
    Pages 22-34

  5. Pharmacological Spectrum of Metipranolol and Experience in Clinical Use

    • W. Bartsch, G. Sponer, K. Strein
    Pages 35-48

  6. Suitability of Metipranolol for Glaucoma Therapy from the Pharmacological Viewpoint

    • E. A. Noack
    Pages 49-61

  7. The Toxicology of Metipranolol with Particular Regard to the Eye

    • W. Sterner
    Pages 62-70

  8. Principles of Clinical Drug Trials

    • G. K. Krieglstein
    Pages 71-75

  9. The Local Anaesthetic Action of Metipranolol Versus Timolol in Patients with Healthy Eyes

    • J. Draeger, R. Winter
    Pages 76-84

  10. Pharmaceutical Development of Eye Drops Using the Product Betamann® as an Example

    • L. Wawretschek
    Pages 85-92

  11. Results of a 6 Weeks’ Multicenter Double-blind Trial Metipranolol Versus Timolol

    • M. Mertz
    Pages 93-105

  12. Therapeutic Efficacy of Metipranolol Eye Drops 0.3% Versus Timolol Eye Drops 0.25%

    • H. Bleckmann, T. Pham Duy, O. Grajewski
    Pages 106-120

  13. Efficacy and Tolerance of Metipranolol — Results of a Multi-center Long-term Study

    • H. von Denffer
    Pages 121-125

  14. Results of a Long-term Study with Metipranolol

    • W. Kruse
    Pages 126-131

  15. Metipranolol Eye Drops — Clinical Suitability in the Treatment of Chronic Open Angle Glaucoma

    • D. Dausch, H. Brewitt, R. Edelhoff
    Pages 132-147

  16. Prophylaxis of an Iatrogenic Increase in Intraocular Pressure

    • P. Schmitz-Valckenberg
    Pages 148-153

  17. Regulating Pressure in Various Forms of Glaucoma with Metipranolol Eye Drops

    • N. Demmler
    Pages 154-162

  18. Supplementary Comments from the Discussion at the Metipranolol Symposium

    • J. Stryz, H. v. Denffer
    Pages 163-170

  19. Back Matter

    Pages 171-171
    Download chapter PDF
Back to top

Keywords

About this book

After a compound and its various effects - or, as the case may be, any particular one of these - have been discovered there is still a long way ahead until it is available for use in daily practice as a finished product. Before reaching the doctor, the substance is examined by chemists, pharmacologists and pharmacists - just to mention a few of the most important stages in a whole research sequence. Before the drug is finally made available on the market, the findings resulting from animal experiments must be confirmed in clinical studies. The expectations involved in its development must be met, and sufficient evidence has to be established as to the drug's effects and side effects, indications and contraindications, and the questions of safe use and appropriate dosage. Only then may the drug be registered and introduced to the market. In this respect Metipranolol eye drops, which have recently been launched on the market, formed no exception and had likewise to go through all these various stages. A series of investigators at many different centers participated in this procedure, and at the invitation of the manufacturers, Messrs. Dr. Gerhard Mann, they assembled for discussions at a symposium held in Berlin in January 1983, and reported on the substance and their experiences with it.

Editors and Affiliations

  • Isar — Technical University, Munich, Federal Republic of Germany

    Hanns-Jürgen Merté

Bibliographic Information

  • Book Title: Metipranolol

  • Book Subtitle: Pharmacology of Beta-blocking Agents and Use of Metipranolol in Ophthalmology

  • Editors: Hanns-Jürgen Merté

  • DOI: https://doi.org/10.1007/978-3-7091-4067-3

  • Publisher: Springer Vienna

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Wien 1984

  • Softcover ISBN: 978-3-211-81824-4Published: 19 June 1984

  • eBook ISBN: 978-3-7091-4067-3Published: 29 June 2013

  • Edition Number: 1

  • Number of Pages: XI, 171

  • Number of Illustrations: 8 b/w illustrations, 1 illustrations in colour

  • Topics: Pharmacology/Toxicology, Ophthalmology, Pharmacy

Publish with us

Policies and ethics

Back to top

Search

Navigation